Co-Existence of SARS-CoV-2 Antibodies with IgG Antibodies of Other Respiratory Viruses: A Possible Risk for Appropriate Adaptive Immune Response
Bennet Angel
1
Shilpa Barthwal
1,2
Neetu Bohra
3
Vinod Joshi
1,*
Annette Angel
1
Shareef Mohammed Buvvaji
1
Bhawna Sharma
1
Received: 22 July 2026 Revised: 14 August 2026 Accepted: 17 September 2026 Published: 22 September 2026
© 2026 The authors. This is an open access article under the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
1. Introduction
All across the world, respiratory viral infections are very common and major contributors of morbidity and mortality. Being aerosol or airborne in nature, these viruses are highly transmissible and have the ability to appear as epidemics and pandemics [1,2,3,4]. Studies have been published on co-infection with the recently emerged SARS-CoV-2 and other respiratory viruses, including Influenza, Rhinovirus, Metapneumovirus, Respiratory Syncytial Virus, and Parainfluenza Virus [5]. Netea and co-workers (2020) conducted research in which they found that majority of people infected with SARS-CoV-2 infection had mild infection, but coinfection can affect their immune systems by making the disease more serious [6]. If we look at the respiratory viruses, most of these are seasonal in appearance. Changes in temperature, humidity, rain, seasonal variations, host immune response, socio-economic settings, workplace, etc., are some of the factors that influence the occurrence of respiratory viral infections at different times [7]. Human metapneumovirus, Rhinovirus, Adenovirus, etc., are some of the viruses that appear throughout the year, while Coronaviruses, Respiratory Syncytial Virus, etc., are considered to be winter viruses. We hypothesize that, since all of these viruses infect the respiratory system and utilize one or the other receptor on the respiratory epithelial cell, they may have a similar mechanism of activation of the adaptive immune response. Both the innate and adaptive immune systems may act targeted when infected by a single virus, as compared to the infection by multiple viruses. We hypothesized that infection through antigenically similar viruses may be hyper immune response in the patients through over cytokines secretions and at the same time, there could be fewer specific antibodies produced by B-cells, which could harm through high molecular weight proteins in the form of IgM and Ig G antibodies.
Present paper reports status of antibodies against multiple respiratory viruses to add to targeted clinical interventions for recovery of patients.
2. Materials and Methods
Blood Samples of patients reporting to Sharda Hospital, U.P, India (period 2021–2022) with respiratory like illness were taken with prior consent. Their symptoms were recorded. The vaccine status of COVID-19 was also recorded (considering the presence of antibodies generated against the vaccine). The blood samples were then brought to Centre of Excellence in Virology and Immunology (BSL-2 level lab) under proper biosafety conditions. The serum was separated, and as per individual protocol, each sample was subjected for ELISA tests. Five major circulating viruses, viz., SARS-CoV-2, Rhino virus, Parainfluenza virus, Influenza Virus A, and Respiratory Syncytial Virus, were selected for detecting IgG Antibody. The kits used were m/s NovaLisa, GmBH for Influenza virus, Parainfluenza Virus A and Respiratory Syncytial Virus, m/s MyBioSource, CA for Rhinovirus, and m/s J.Mitra, India for SARS-CoV-2 antibody detection.
The expected reference values for Influenza Virus A detection were as follows: Optical Density (OD) for Negative Control (NC): 0.068, Cut off value: 0.732, and OD of Positive control (PC): 1.408. The expected reference values for Parainfluenza Virus detection were as follows: OD of blank: 0.047, OD of NC: 0.064, Cut off value: 0.926, and OD of PC: 1.831. The expected reference values for Respiratory Syncytial Virus detection were as follows: OD for blank: 0.055, OD of NC: 0.065, Cut off value: 1.097, and OD of PC: 2.312. The expected reference values for Rhino Virus detection were as follows: OD blank: 0.046, OD of NC: 0.114, Cut off value: 0.255, and OD of PC: 1.769. The expected reference values for Rhino Virus detection were as follows: NC $$\bar{X}\mathrm{ }$$= 0.1585, Cut off value = 0.3585, PC = 2.066, final calculation for Covid antibodies unit = Sample O.D. ratio × 10.
3. Results
Table 1, Table 2, Table 3 and Table 4 represent the occurrence of antibodies against various respiratory viruses, along with vaccination status, in each individual. It was observed that all the subjects were infected with more than one respiratory virus and that the maximum subjected had been administered the COVID-19 vaccine. Table 1 indicates that out of the total 92 subjects studied, 13 (14.13%) had antibodies for two respiratory viruses. Of these, 84.6% had taken the COVID-19 vaccine. Of the 5 viruses studied, it was analyzed that antibodies for SARS-CoV-2 and Parainfluenza virus were found to coexist in maximum cases (Table 1).
Table 1. Presence of Antibodies against two Respiratory Viruses in study subjects.
|
S.No. |
Sample Code |
Age |
Sex (M/F) |
COVID Vaccination |
SAR-CoV-2 Virus IgGAb |
Influenza Virus A IgG Ab |
Parainfluenza Virus IgGAb |
Respiratory Syncytial Virus IgG Ab |
Rhino Virus IgG Ab |
|---|---|---|---|---|---|---|---|---|---|
|
1. |
SUAb/2022/28 |
32 |
F |
No |
√ |
N |
N |
√ |
N |
|
2. |
SUAb/2022/203 |
18 |
F |
√ |
√ |
N |
√ |
N |
N |
|
3. |
SUAb/2022/140 |
18 |
F |
√ |
√ |
N |
√ |
N |
N |
|
4. |
SUAb/2022/70 |
24 |
F |
√ |
√ |
Eq |
√ |
N |
N |
|
5. |
SUAb/2022/187 |
19 |
F |
√ |
√ |
N |
√ |
N |
N |
|
6. |
SUAb/2022/105 |
19 |
F |
√ |
√ |
Eq |
√ |
N |
N |
|
7. |
SUAb/2022/141 |
21 |
F |
√ |
√ |
N |
√ |
N |
N |
|
8. |
SUAb/2022/236 |
25 |
F |
√ |
√ |
N |
√ |
N |
N |
|
9. |
SUAb/2022/183 |
18 |
M |
√ |
√ |
Eq |
√ |
N |
N |
|
10. |
SUAb/2022/121 |
25 |
M |
√ |
√ |
N |
√ |
N |
N |
|
11. |
SUAb/2022/250 |
62 |
M |
√ |
ND * |
√ |
√ |
Eq |
N |
|
12. |
SUAb/2022/269 |
71 |
M |
√ |
ND * |
√ |
√ |
N |
N |
|
13. |
SUAb/2022/276 |
62 |
M |
No |
ND * |
N |
√ |
Eq |
√ |
|
Total |
11 |
10 |
2 |
12 |
1 |
1 |
|||
|
% contribution |
84.61 |
76.92 |
15.3 |
92.30 |
7.69 |
7.69 |
* ND = Not done; Eq = Equivalent; N = Negative; √ = Present.
Table 2 indicates that out of the total 92 subjects studied, 36 (39.13%) had antibodies for three respiratory viruses. Of these, 97.2% had taken the COVID-19 vaccine. The table showed that antibodies that co-existed in maximum cases were SARS-CoV-2, Influenza A, and Parainfluenza virus.
Table 2. Presence of Antibodies against three Respiratory Viruses in study subjects.
|
S.No. |
Sample Code |
Age |
Sex |
COVID Vaccination |
SAR-CoV-2 Virus IgGAb |
Influenza Virus A IgG Ab |
Parainfluenza Virus IgGAb |
Respiratory Syncytial Virus IgG Ab |
Rhino Virus IgG Ab |
|---|---|---|---|---|---|---|---|---|---|
|
1. |
SUAb/2022/71 |
25 |
F |
No |
√ |
√ |
N |
Eq |
√ |
|
2. |
SUAb/2022/224 |
25 |
F |
√ |
√ |
Eq |
√ |
√ |
N |
|
3. |
SUAb/2022/53 |
58 |
M |
√ |
√ |
Eq |
√ |
√ |
N |
|
4. |
SUAb/2022/42 |
40 |
F |
√ |
√ |
N |
√ |
√ |
N |
|
5. |
SUAb/2022/145 |
22 |
M |
√ |
√ |
Eq |
√ |
√ |
N |
|
6. |
SUAb/2022/55 |
30 |
F |
√ |
√ |
N |
√ |
Eq |
√ |
|
7. |
SUAb/2022/51 |
34 |
M |
√ |
√ |
√ |
√ |
Eq |
N |
|
8. |
SUAb/2022/91 |
22 |
F |
√ |
√ |
√ |
√ |
Eq |
N |
|
9. |
SUAb/2022/114 |
26 |
F |
√ |
√ |
√ |
√ |
Eq |
N |
|
10. |
SUAb/2022/189 |
18 |
F |
√ |
√ |
√ |
√ |
N |
N |
|
11. |
SUAb/2022/146 |
19 |
F |
√ |
√ |
√ |
√ |
N |
N |
|
12. |
SUAb/2022/123 |
18 |
M |
√ |
√ |
√ |
√ |
N |
N |
|
13. |
SUAb/2022/185 |
18 |
M |
√ |
√ |
√ |
√ |
N |
N |
|
14. |
SUAb/2022/199 |
21 |
M |
√ |
√ |
√ |
√ |
N |
N |
|
15. |
SUAb/2022/154 |
19 |
M |
√ |
√ |
√ |
√ |
N |
N |
|
16. |
SUAb/2022/01 |
66 |
M |
√ |
√ |
Eq |
√ |
√ |
N |
|
17. |
SUAb/2022/50 |
56 |
M |
√ |
√ |
√ |
√ |
Eq |
N |
|
18. |
SUAb/2022/06 |
31 |
F |
√ |
√ |
N |
√ |
√ |
N |
|
19. |
SUAb/2022/243 |
57 |
M |
√ |
ND * |
√ |
√ |
√ |
N |
|
20. |
SUAb/2022/244 |
68 |
M |
√ |
ND * |
√ |
√ |
√ |
N |
|
21. |
SUAb/2022/249 |
51 |
M |
√ |
ND * |
√ |
√ |
√ |
N |
|
22. |
SUAb/2022/252 |
60 |
M |
√ |
ND * |
√ |
√ |
√ |
N |
|
23. |
SUAb/2022/245 |
60 |
F |
√ |
ND * |
√ |
√ |
√ |
N |
|
24. |
SUAb/2022/264 |
36 |
M |
√ |
ND * |
√ |
√ |
N |
√ |
|
25. |
SUAb/2022/247 |
67 |
F |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
26. |
SUAb/2022/255 |
75 |
M |
√ |
ND * |
Eq |
√ |
√ |
√ |
|
27. |
SUAb/2022/266 |
55 |
F |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
28. |
SUAb/2022/270 |
73 |
F |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
29. |
SUAb/2022/281 |
44 |
M |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
30. |
SUAb/2022/284 |
30 |
M |
√ |
ND * |
Eq |
√ |
√ |
√ |
|
31. |
SUAb/2022/283 |
70 |
M |
√ |
ND * |
√ |
√ |
N |
√ |
|
32. |
SUAb/2022/280 |
67 |
M |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
33. |
SUAb/2022/291 |
49 |
M |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
34. |
SUAb/2022/289 |
27 |
F |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
35. |
SUAb/2022/287 |
24 |
M |
√ |
ND * |
√ |
√ |
N |
√ |
|
36. |
SUAb/2022/286 |
25 |
F |
√ |
ND * |
√ |
√ |
Eq |
√ |
|
Total |
35 |
18 |
27 |
35 |
13 |
15 |
|||
|
% contribution |
97.2 |
50 |
75 |
97.2 |
36.1 |
41.6 |
* ND = Not done; Eq = Equivalent; N = Negative; √ = Present.
Table 3 indicates that out of the total 92 subjects studied, 33 (35.86%) had antibodies for four respiratory viruses, of which 93.9% had taken the COVID-19 vaccine. Table 4 indicates that out of the total 92 subjects studied, 10 (10.86%) had antibodies for five respiratory viruses, and all of these were administered the COVID-19 vaccine.
Co-infection status indicated that out of 92, there were 19 patients who suffered from breathlessness, one (SUAb/2022/253) had Tuberculosis, and one (SUAb/2022/282) had hypertension (since past 10–15 years) and lung infection.
Table 3. Presence of Antibodies against four Respiratory Viruses in study subjects.
|
S.No. |
Sample Code |
Age |
Sex |
COVID Vaccination |
SAR-CoV-2 Virus IgG Ab |
Influenza Virus A IgG Ab |
Parainfluenza Virus IgG Ab |
Respiratory Syncytial Virus IgG Ab |
Rhino Virus IgG Ab |
|---|---|---|---|---|---|---|---|---|---|
|
1. |
SUAb/2022/96 |
39 |
F |
No |
√ |
√ |
√ |
√ |
N |
|
2. |
SUAb/2022/234 |
21 |
F |
√ |
√ |
√ |
√ |
√ |
N |
|
3. |
SUAb/2022/226 |
23 |
F |
√ |
√ |
√ |
√ |
√ |
N |
|
4. |
SUAb/2022/44 |
35 |
F |
√ |
√ |
√ |
√ |
√ |
N |
|
5. |
SUAb/2022/101 |
21 |
M |
√ |
√ |
N |
√ |
√ |
√ |
|
6. |
SUAb/2022/171 |
19 |
M |
√ |
√ |
√ |
√ |
√ |
N |
|
7. |
SUAb/2022/36 |
45 |
F |
√ |
√ |
N |
√ |
√ |
√ |
|
8. |
SUAb/2022/12 |
36 |
F |
√ |
√ |
√ |
√ |
N |
√ |
|
9. |
SUAb/2022/7 |
26 |
F |
√ |
√ |
√ |
√ |
N |
√ |
|
10. |
SUAb/2022/57 |
27 |
F |
√ |
√ |
√ |
√ |
N |
√ |
|
11. |
SUAb/2022/109 |
35 |
F |
√ |
√ |
√ |
√ |
Eq |
√ |
|
12. |
SUAb/2022/56 |
32 |
F |
√ |
√ |
√ |
√ |
N |
√ |
|
13. |
SUAb/2022/27 |
41 |
M |
√ |
√ |
√ |
√ |
N |
√ |
|
14. |
SUAb/2022/45 |
49 |
M |
√ |
√ |
N |
√ |
√ |
√ |
|
15. |
SUAb/2022/66 |
28 |
M |
√ |
√ |
Eq |
√ |
√ |
√ |
|
16. |
SUAb/2022/173 |
19 |
M |
√ |
√ |
N |
√ |
√ |
√ |
|
17. |
SUAb/2022/174 |
18 |
M |
√ |
√ |
N |
√ |
√ |
√ |
|
18. |
SUAb/2022/178 |
18 |
M |
√ |
√ |
√ |
√ |
√ |
N |
|
19. |
SUAb/2022/176 |
19 |
F |
√ |
√ |
N |
√ |
√ |
√ |
|
20. |
SUAb/2022/92 |
29 |
F |
√ |
√ |
√ |
√ |
√ |
N |
|
21. |
SUAb/2022/108 |
27 |
M |
√ |
√ |
√ |
√ |
√ |
N |
|
22. |
SUAb/2022/33 |
30 |
M |
√ |
√ |
N |
√ |
√ |
√ |
|
23. |
SUAb/2022/34 |
40 |
M |
√ |
√ |
√ |
√ |
√ |
N |
|
24. |
SUAb/2022/265 |
48 |
M |
√ |
ND * |
√ |
√ |
√ |
√ |
|
25. |
SUAb/2022/253 |
65 |
F |
√ |
ND * |
√ |
√ |
√ |
√ |
|
26. |
SUAb/2022/254 |
82 |
M |
√ |
ND * |
√ |
√ |
√ |
√ |
|
27. |
SUAb/2022/262 |
70 |
M |
√ |
ND * |
√ |
√ |
√ |
√ |
|
28. |
SUAb/2022/268 |
57 |
F |
√ |
ND * |
√ |
√ |
√ |
√ |
|
29. |
SUAb/2022/282 |
71 |
M |
√ |
ND * |
√ |
√ |
√ |
√ |
|
30. |
SUAb/2022/292 |
66 |
M |
√ |
ND * |
√ |
√ |
√ |
√ |
|
31. |
SUAb/2022/275 |
78 |
M |
√ |
ND * |
√ |
√ |
√ |
√ |
|
32. |
SUAb/2022/263 |
54 |
M |
No |
ND * |
√ |
√ |
√ |
√ |
|
33. |
SUAb/2022/11 |
67 |
F |
√ |
√ |
√ |
√ |
√ |
N |
|
Total |
31 |
24 |
25 |
33 |
27 |
23 |
|||
|
% contribution |
93.9 |
72.7 |
75.7 |
100 |
81.8 |
71.8 |
* ND = Not done; Eq = Equivalent; N = Negative. √ = Present.
Table 4. Presence of Antibodies against five Respiratory Viruses & COVID-19 vaccination status in study subjects.
|
S.No. |
Sample Code |
Age |
Sex |
COVID Vaccination |
SAR-CoV-2 Virus IgGAb |
Influenza Virus A IgG Ab |
Parainfluenza Virus IgGAb |
Respiratory Syncytial Virus IgG Ab |
Rhino Virus IgG Ab |
|---|---|---|---|---|---|---|---|---|---|
|
1. |
SUAb/2022/230 |
21 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
2. |
SUAb/2022/100 |
22 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
3. |
SUAb/2022/93 |
28 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
4. |
SUAb/2022/38 |
27 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
5. |
SUAb/2022/153 |
19 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
6. |
SUAb/2022/43 |
31 |
M |
√ |
√ |
√ |
√ |
√ |
√ |
|
7. |
SUAb/2022/152 |
19 |
M |
√ |
√ |
√ |
√ |
√ |
√ |
|
8. |
SUAb/2022/94 |
29 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
9. |
SUAb/2022/04 |
25 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
10. |
SUAb/2022/10 |
26 |
F |
√ |
√ |
√ |
√ |
√ |
√ |
|
Total |
10 |
10 |
10 |
10 |
10 |
10 |
|||
|
% contribution |
100 |
100 |
100 |
100 |
100 |
100 |
√ = Present.
When the overall status was checked it was observed that presence of IgG for Parainfluenza A virus was present in maximum study subjects (92.30 to 100%) along with IgG for SARS-CoV-2 (50–76.92%). Almost all these study subjects, 84.61–100%, were vaccinated during the COVID-19 period (Table 5).
Table 5. Summation of Presence of Antibodies against Respiratory Viruses in study subjects.
|
S.No. |
IgG Categories and COVID-19 Vaccination Status |
Presence of IgG Against Number (N) of Respiratory Viruses |
|||
|---|---|---|---|---|---|
|
N = 2 |
N = 3 |
N = 4 |
N = 5 |
||
|
1. |
SAR-CoV-2 Virus IgGAb |
76.92 |
50.00 |
72.70 |
100 |
|
2. |
Influenza Virus A IgG Ab |
15.30 |
75.00 |
75.70 |
100 |
|
3. |
Parainfluenza Virus IgGAb |
92.30 |
97.2 |
100 |
100 |
|
4. |
Respiratory Syncytial Virus IgG Ab |
7.69 |
36.1 |
81.8 |
100 |
|
5. |
Rhino Virus IgG Ab |
7.69 |
41.6 |
71.8 |
100 |
|
6. |
COVID vaccination status |
84.61 |
97.2 |
93.9 |
100 |
4. Discussion
IgM antibodies are produced by B cells at the rate of 2000/s. There are positive and negative feedback mechanisms that work during the production of antibodies. There is also addition of glucose residues and sialic acid residues in the crystal structure of the antibodies [8,9].
Production of antibodies by B cells against a specific pathogen is the result of a non-covalent binding between the amino acid ligand of the pathogen (epitope) and the B cell receptor or naïve membrane bound antibody molecules (paratope). The chemical reaction occurs between epitope and paratope as collective strengths of hydrogen bonds and Vanderwal’s bond, etc. Reading an epitope amino acid constitution is conveyed to the nucleus of B-cells, where a gene rearrangement takes place, and programmed B cells produce specific antibodies. This entire process of antibody production is activated by the secretion of cytokines by T helper cells. In the event of co-infection by antigenically different, but sequentially similar (in amino acid sequence) respiratory viruses, there is a possibility of non-specific antibodies and an inappropriate level of cytokines. Therefore, possibility of cytokines storm and accumulation of non-targeted antibodies, which are high molecular weight protein and if not joined to epitopes, can lead to generation of antibody enhanced infection.
The limitation of the present study is that the SARS-CoV-2 antibody assay kits available in the market, including the one used in this study, are not able to distinguish vaccine-induced antibodies from those generated following natural infection. Another limitation of the present work is that there was not a sufficient number of study subjects for statistical analysis.
5. Conclusions
Results of the present study indicate the presence of more than three different types of IgG antibodies against respiratory viruses in COVID-19 patients. Interaction of multiple viral ligands with B cells and T cells may result in the production of less specific antibodies and hypo- or hypercytokine levels. The study reveals preliminary observations and necessitates further studies on antibodies and cytokines.
Author Contributions
Conceptualization, V.J.; Methodology, S.B., B.A., A.A., S.M.B., B.S. and N.B.; Validation, S.B., B.A., A.A., S.M.B., B.S., V.J. and N.B.; Formal Analysis, S.B., B.A., A.A., S.M.B., B.S., V.J. and N.B.; Investigation, S.B., B.A., A.A. and V.J.; Resources, S.B., S.M.B. and B.S.; Data Curation, S.B., S.M.B. and B.S.; Writing—Original Draft Preparation, S.B., B.A., A.A. and V.J.; Writing—Review & Editing, S.B., B.A., A.A., S.M.B., B.S., V.J. and N.B.; Supervision, V.J., B.A. and A.A.; Project Administration, V.J.; Funding Acquisition, B.A.
Ethics Statement
The study has been approved by the Institutional Ethical Committee, Sharda University, India (SU/SMS&R/76-A/2021/112, dated 03/09/2021).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
All data pertaining to the study are included in this paper.
Funding
This research was funded by Indian Council of Medical Research, (ICMR), Govt of India, grant number [2021-6369].
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- Aggarwal N, Potdar V, Vijay N, Mukhopadhyay L, Borkakoty B, Manjusree S, et al. SARS-CoV-2 and Influenza Virus Co-Infection Cases Identified through ILI/SARI Sentinel Surveillance: A Pan-India Report. Viruses 2022, 14, 627. DOI:10.3390/v14030627 [Google Scholar]
- van Doorn HR, Yu H. Viral Respiratory Infections. In Hunter’s Tropical Medicine and Emerging Infectious Diseases; Elsevier: Amsterdam, The Netherlands, 2020; pp. 284–288. DOI:10.1016/B978-0-323-55512-8.00033-8 [Google Scholar]
- Bonguili NCB, Mombo IM, Lenguiya LH, Lattaphasavang V, Pabouriboune P, Deharo E, et al. Etiology and epidemiology of respiratory infections in community-based influenza-like illness during the COVID-19 pandemic, Vientiane, Lao People’s Democratic Republic. Int. J. Infect. Dis. 2025, 161, 108079. DOI:10.1016/j.ijid.2025.108079 [Google Scholar]
- Schüz ML, Dallmeyer L, Fragkou PC, Omony J, Krumbein H, Hünerbein BL, et al. Global prevalence of respiratory virus infections in adults and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis. Int. J. Infect. Dis. 2023, 137, 16–24. DOI:10.1016/j.ijid.2023.10.001 [Google Scholar]
- Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol. 2020, 104, 7777–7785. DOI:10.1007/s00253-020-10814-6 [Google Scholar]
- Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R, van de Veerdonk FL, et al. Trained Immunity: A Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell 2020, 181, 969–977. DOI:10.1016/j.cell.2020.04.042 [Google Scholar]
- Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu. Rev. Virol. 2020, 7, 83–101. DOI:10.1146/annurev-virology-012420-022445 [Google Scholar]
- Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014, 5, 520. DOI:10.3389/fimmu.2014.00520 [Google Scholar]
- Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin. J. Am. Soc. Nephrol. 2016, 11, 137–154. DOI:10.2215/CJN.09430915 [Google Scholar]